このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

AnteoTech 将来の成長

Future 基準チェック /06

現在、 AnteoTechの成長と収益を予測するのに十分なアナリストの調査がありません。

主要情報

n/a

収益成長率

n/a

EPS成長率

Chemicals 収益成長	29.6%
収益成長率	n/a
将来の株主資本利益率	n/a
アナリストカバレッジ	None
最終更新日	n/a

今後の成長に関する最新情報

更新なし

Recent updates

このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、AnteoTech は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。

シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。

業績と収益の成長予測

ASX:ADO - アナリストの将来予測と過去の財務データ ( )AUD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2023	1	-11	-7	-7	N/A
9/30/2023	1	-12	-8	-7	N/A
6/30/2023	0	-13	-9	-8	N/A
3/31/2023	1	-12	-10	-8	N/A
12/31/2022	2	-10	-10	-9	N/A
9/30/2022	1	-11	-11	-9	N/A
6/30/2022	1	-11	-12	-9	N/A
3/31/2022	1	-10	-11	-8	N/A
12/31/2021	1	-9	-9	-7	N/A
9/30/2021	1	-7	-7	-6	N/A
6/30/2021	1	-6	-5	-5	N/A
3/31/2021	1	-5	-3	-3	N/A
12/31/2020	2	-3	-1	-1	N/A
9/30/2020	2	-3	-2	-2	N/A
6/30/2020	1	-3	-3	-3	N/A
3/31/2020	1	-3	-3	-3	N/A
12/31/2019	1	-3	-3	-3	N/A
9/30/2019	1	-3	-3	-3	N/A
6/30/2019	0	-3	-2	-2	N/A
3/31/2019	1	-3	-3	-2	N/A
12/31/2018	1	-2	-3	-3	N/A
9/30/2018	1	-3	-4	-4	N/A
6/30/2018	1	-3	-5	-5	N/A
12/31/2017	0	-5	-4	-3	N/A
9/30/2017	1	-6	N/A	-2	N/A
6/30/2017	2	-7	N/A	0	N/A
12/31/2016	4	-9	N/A	-4	N/A
9/30/2016	3	-8	N/A	-5	N/A
6/30/2016	2	-7	N/A	-7	N/A
3/31/2016	7	-5	N/A	-7	N/A
12/31/2015	1	-5	N/A	-7	N/A
9/30/2015	1	-5	N/A	-5	N/A
6/30/2015	0	-4	N/A	-3	N/A
3/31/2015	0	-4	N/A	-3	N/A
12/31/2014	0	-4	N/A	-3	N/A
9/30/2014	0	-3	N/A	-2	N/A
6/30/2014	0	-2	N/A	-2	N/A
3/31/2014	0	-2	N/A	-2	N/A
12/31/2013	0	-2	N/A	-2	N/A
9/30/2013	0	-2	N/A	-2	N/A
6/30/2013	0	-2	N/A	-2	N/A

アナリストによる今後の成長予測

収入対貯蓄率: ADOの予測収益成長が貯蓄率 ( 2.3% ) を上回っているかどうかを判断するにはデータが不十分です。

収益対市場: ADOの収益がAustralian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です

高成長収益: ADOの収益が今後 3 年間で大幅に増加すると予想されるかどうかを判断するにはデータが不十分です。

収益対市場: ADOの収益がAustralian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。

高い収益成長: ADOの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: ADOの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

AnteoTech 将来の成長

Future 基準チェック /06

主要情報

今後の成長に関する最新情報

Recent updates

New minor risk - Share price stability

AnteoTech Limited, Annual General Meeting, May 28, 2024

AnteoTech Limited has completed a Follow-on Equity Offering in the amount of AUD 5.4 million.

AnteoTech Limited has filed a Follow-on Equity Offering in the amount of AUD 2.5 million.

We're Keeping An Eye On AnteoTech's (ASX:ADO) Cash Burn Rate

AnteoTech Limited to Report First Half, 2024 Results on Feb 28, 2024

AnteoTech Limited, Annual General Meeting, Nov 14, 2023

AnteoTech Limited, Annual General Meeting, Nov 14, 2023

Full year 2023 earnings released: AU$0.006 loss per share (vs AU$0.005 loss in FY 2022)

New minor risk - Financial data availability

Anteotech Limited Announces Appointment of Mr. Andrew Cook as Chief Financial Officer

AnteoTech Limited to Report Fiscal Year 2023 Results on Aug 30, 2023

New major risk - Share price stability

AnteoTech Limited Announces Retirement of Christopher Parker from the Board of Directors

Will AnteoTech (ASX:ADO) Spend Its Cash Wisely?

Board Member exercised options to buy AU$70k worth of stock.

First half 2023 earnings released: AU$0.002 loss per share (vs AU$0.002 loss in 1H 2022)

AnteoTech Limited Appoints Tsui Min Lian as Chief Marketing Officer, Effective 15 March 2023

Non-Executive Director recently sold AU$61k worth of stock

Is AnteoTech (ASX:ADO) In A Good Position To Invest In Growth?

High number of new and inexperienced directors

AnteoTech Ltd Announces Halt of European Rat Clinical Trial to Refocus Initiatives

AnteoTech Limited Appoint Executives

Full year 2022 earnings released: AU$0.005 loss per share (vs AU$0.003 loss in FY 2021)

AnteoTech Limited, Annual General Meeting, Nov 17, 2022

Companies Like AnteoTech (ASX:ADO) Are In A Position To Invest In Growth

AnteoTech Limited Appoints David Radford as Managing Director, Effective from 4 October 2022

AnteoTech Limited SHS to Be Deleted from OTC Equity

Non-Executive Director recently sold AU$106k worth of stock

AnteoTech Ltd Announces Updated COVID-19 RAT Receives Regulatory Approval in Europe

Non-Executive Director recently sold AU$220k worth of stock

High number of new and inexperienced directors

AnteoTech Limited Announces Executive Changes

Companies Like AnteoTech (ASX:ADO) Are In A Position To Invest In Growth

First half 2022 earnings: EPS in line with analyst expectations despite revenue beat

AnteoTech Limited Provides Update on Its Therapeutic Goods Administration Submission

AnteoTech Limited Provides Update on Its Therapeutic Goods Administration Submission

Non-Executive Director recently sold AU$108k worth of stock

Company Secretary Duncan Cornish has left the company

High number of new and inexperienced directors

We Think AnteoTech (ASX:ADO) Can Easily Afford To Drive Business Growth

High number of new and inexperienced directors

Independent Non-Executive Director recently bought AU$59k worth of stock

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Full year 2021 earnings released: AU$0.003 loss per share (vs AU$0.002 loss in FY 2020)

Chief Financial Officer Gail Jukes has left the company

Non-Executive Director recently sold AU$112k worth of stock

AnteoTech Limited has completed a Follow-on Equity Offering in the amount of AUD 12.000001 million.

AnteoTech Limited announced that it expects to receive AUD 12.000001 million in funding

We Think AnteoTech (ASX:ADO) Can Easily Afford To Drive Business Growth

Independent Non-Executive Director has left the company

First half 2021 earnings released: AU$0.001 loss per share (vs AU$0.001 loss in 1H 2020)

New 90-day high: AU$0.21

AnteoTech Customer Ellume Secures Us Contract

We're Not Very Worried About AnteoTech's (ASX:ADO) Cash Burn Rate

AnteoTech Progresses COVID-19 Test Toward Market Launch

AnteoTech Ltd Freeze Design of COVID-19 Antigen Rapid Test After Showing Saliva Proxy Sample Use Case Effectiveness

Independent Non-Executive Director exercised options to buy AU$208k worth of stock.

Full year earnings released - AU$0.002 loss per share

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘